Trial Profile

Randomized Open Label Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 29 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Immune globulin (Primary) ; Methylprednisolone
Indications Acute lung injury; COVID-19 pneumonia; Hypoxia; Respiratory insufficiency
Focus Therapeutic Use

Most Recent Events

23 Jun 2021 Status changed from active, no longer recruiting to completed.
02 Dec 2020 Results published in the Octapharma Media Release.
02 Dec 2020 According to an Octapharma media release, data from this study will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com